Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Cornelius

Showing results (101-110 of 106) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 106 results.
Bioorganic & Medicinal Chemistry Letters|May 16, 2008
Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitorsZhen-Wei Cai, Donna Wei, Gretchen M Schroeder, et al.
Bioorganic & Medicinal Chemistry Letters|January 22, 2017
Discovery of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent and selective PI3Kδ inhibitorsLan-Ying Qin, Zheming Ruan, Robert J Cherney, et al.
Journal of Medicinal Chemistry|December 24, 2004
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assaysLouis J Lombardo, Francis Y Lee, Ping Chen, et al.
Minimally Invasive Therapy & Allied Technologies : MITAT : Official Journal of the Society for Minimally Invasive Therapy|February 17, 2010
The medical engineering program of Forschungszentrum KarlsruheH Fischer, M Selig, J Vagner, et al.
Journal of Medicinal Chemistry|March 6, 2009
Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamilyGretchen M Schroeder, Yongmi An, Zhen-Wei Cai, et al.
ACS Medicinal Chemistry Letters|June 20, 2020
Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse AgonistRobert J Cherney, Lyndon A M Cornelius, Anurag Srivastava, et al.
Pageof 11

Showing results (101-110 of 106) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 106 results.
Bioorganic & Medicinal Chemistry Letters|May 16, 2008
Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitorsZhen-Wei Cai, Donna Wei, Gretchen M Schroeder, et al.
Bioorganic & Medicinal Chemistry Letters|January 22, 2017
Discovery of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent and selective PI3Kδ inhibitorsLan-Ying Qin, Zheming Ruan, Robert J Cherney, et al.
Journal of Medicinal Chemistry|December 24, 2004
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assaysLouis J Lombardo, Francis Y Lee, Ping Chen, et al.
Minimally Invasive Therapy & Allied Technologies : MITAT : Official Journal of the Society for Minimally Invasive Therapy|February 17, 2010
The medical engineering program of Forschungszentrum KarlsruheH Fischer, M Selig, J Vagner, et al.
Journal of Medicinal Chemistry|March 6, 2009
Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamilyGretchen M Schroeder, Yongmi An, Zhen-Wei Cai, et al.
ACS Medicinal Chemistry Letters|June 20, 2020
Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse AgonistRobert J Cherney, Lyndon A M Cornelius, Anurag Srivastava, et al.
Pageof 11